The pharmaceutical company announced the launch of Spirofy, the first portable wireless pneumotache-based spirometer in India.
With this launch, Cipla intends to revolutionize the diagnosis of obstructive airway diseases (OAM), in line with its ambition to strengthen its position as the lung leader in India.
Spirofy is India’s first portable wireless pneumotache-based spirometer for the diagnosis of chronic obstructive pulmonary disease (COPD) and asthma.
The device guarantees high accuracy of results and individual patient safety using bacterial virus filters. Spirofy is fully wireless with good battery backup, making it suitable for use in outdoor camps, remote areas with power outages, or simply to provide flexibility and ease of use for doctors. The device generates real-time reports, which can be printed instantly using a portable wireless thermal printer, or a pdf version can be shared on the phone. Cipla will undertake training of physicians in the interpretation of spirometry results.
Currently, COPD remains the 2nd most common cause of death in India after heart disease, where India alone bears 32% of the global burden of COPD.
Umang Vohra (MD and Global CEO of Cipla) said, “Cipla has resolutely focused on tackling the growing burden of respiratory disease around the world, and with this launch we see ourselves making steady progress in the fight against disease. chronic respiratory diseases such as COPD. The launch of Spirofy aims to help physicians across the country improve the lives of patients through accurate and affordable diagnosis. ”
The pharmaceutical major’s consolidated net profit increased 7% year-on-year to Rs 711 crore, with total operating income increasing 10% to Rs 5,520 crore in the second quarter of fiscal year 22 from report for the second quarter of fiscal year 21.
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics and portfolio deepening in our home markets of India, South Africa, North America and major regulated markets and emerging. Our strengths in the respiratory, antiretroviral, urological, cardiological, anti-infective and CNS segments are recognized.
Cipla shares were down 0.98% to Rs 912.05 on BSE.
Powered by Capital Market – Live News
(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)